Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Pegasys

Boehringer Ingelheim headquarters

Boehringer stops Gilotrif head and neck cancer trials

Trial data suggests the drug is “highly unlikely” to prolong patients’ remission

- PMLiVE

EMA suspends generic drugs on data integrity concerns

Reports by FDA and WHO find evidence of data manipulation by Semler Research Centre

- PMLiVE

Gilead’s universal hep C therapy Epclusa approved in EU

European nod for first pan-genotypic treatment follows recent FDA licensing

Roche Basel Switzerland

Roche says Tecentriq “off to a good start”

Bladder cancer therapy drug seems set for rapid growth

Roche Basel Switzerland

Roche’s Gazyvaro flunks trial in non-Hodgkin’s lymphoma

Failed to improve progression-free survival when compared with its MabThera/Rituxan therapy

EU flag

EC approves Bial’s Parkinson’s disease therapy

Ongentys will be given a phase roll-out in 2016 and 2017

- PMLiVE

FDA approves Gilead’s ‘universal’ hep C combination Epclusa

Adds a third Sovaldi-based treatment to the firm’s portfolio

Roche Basel Switzerland

Roche’s MS drug Ocrevus awarded priority review by FDA

Comes as Swiss company files the therapy with the FDA and EMA

ABPI London offices

Compliance cover-up sees Astellas suspended from ABPI

Code of Practice watchdog says it's one of the worst cases it has ever seen

- PMLiVE

Ariad files early marketing application for brigatinib

Second-line lung cancer therapy could be on the market by early 2017

Bristol-Myers Squibb (BMS) building

Speedy NICE appraisal backs BMS’ Opdivo/Yervoy combination

But HTA body doesn't find Roche's Cotellic/Zelboraf cost-effective

Roche Basel Switzerland

Roche’s Gazyvaro cleared for follicular lymphoma in Europe

Second indication anticipated to increase peak sales by up to $1bn

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links